Benjamin Peter Geisler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7996929/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Meniscus Root Repair vs Meniscectomy or Nonoperative Management to Prevent Knee Osteoarthritis After Medial Meniscus Root Tears: Clinical and Economic Effectiveness. American Journal of Sports Medicine, 2019, 47, 762-769.	4.2	156
2	Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension. Journal of the American College of Cardiology, 2012, 60, 1271-1277.	2.8	126
3	Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. , 2015, 3, 4.		122
4	Use of Observation Care in US Emergency Departments, 2001 to 2008. PLoS ONE, 2011, 6, e24326.	2.5	112
5	Utility Estimates for Decision–Analytic Modeling in Chronic Heart Failure—Health States Based on New York Heart Association Classes and Number of Rehospitalizations. Value in Health, 2009, 12, 185-187.	0.3	98
6	Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK. BMJ Open, 2016, 6, e011245.	1.9	60
7	Economic analysis of endovascular interventions for femoropopliteal arterial disease: A systematic review and budget impact model for the United States and Germany. Catheterization and Cardiovascular Interventions, 2014, 84, 546-554.	1.7	51
8	Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure. Pharmacoeconomics, 2011, 29, 753-769.	3.3	31
9	Estimates of Electronic Medical Records in U.S. Emergency Departments. PLoS ONE, 2010, 5, e9274.	2.5	29
10	Racial/ethnic and socioeconomic variations in hospital length of stay. Medicine (United States), 2021, 100, e25976.	1.0	28
11	Racial and Geographic Disparities in Interhospital ICU Transfers*. Critical Care Medicine, 2018, 46, e76-e80.	0.9	27
12	Decisionâ€analytic evaluation of the clinical effectiveness and costâ€effectiveness of management programmes in chronic heart failure. European Journal of Heart Failure, 2008, 10, 1026-1032.	7.1	26
13	Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients at lower surgical risk: results from the NOTION trial. EuroIntervention, 2019, 15, e959-e967.	3.2	23
14	Outcomes of Ventilated Patients With Sepsis Who Undergo Interhospital Transfer: A Nationwide Linked Analysis*. Critical Care Medicine, 2018, 46, e81-e86.	0.9	20
15	Utilizing a <scp>PLASMIC</scp> scoreâ€based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard <scp>TMA</scp> Research Collaborative. British Journal of Haematology, 2019, 186, 490-498.	2.5	20
16	Model to evaluate the impact of hospital-based interventions targeting false-positive blood cultures on economic and clinical outcomes. Journal of Hospital Infection, 2019, 102, 438-444.	2.9	14
17	Cost-effectiveness and cost-utility of a structured collaborative disease management in the Interdisciplinary Network for Heart Failure (INH) study. Clinical Research in Cardiology, 2015, 104, 304-309.	3.3	13
18	Clinical and Economic Benefits of Upper Airway Stimulation for Obstructive Sleep Apnea in a European Setting. Respiration, 2019, 98, 38-47.	2.6	13

#	Article	IF	CITATIONS
19	Value in Oral and Maxillofacial Surgery: A Systematic Review of Economic Analyses. Journal of Oral and Maxillofacial Surgery, 2017, 75, 2287-2303.	1.2	12
20	Cost-Effectiveness and Projected Survival of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement for High Risk Patients in a European Setting: A Dutch Analysis Based on the CoreValve High Risk Trial. Structural Heart, 2017, 1, 267-274.	0.6	9
21	Blood pressure control in Australian general practice: analysis using general practice records of 1.2 million patients from the MedicineInsight database. Journal of Hypertension, 2021, 39, 1134-1142.	0.5	9
22	Trauma and Burn Education: A Global Survey. World Journal of Surgery, 2012, 36, 548-555.	1.6	8
23	Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1223-1232.	1.1	8
24	Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic. Pharmacoeconomics, 2021, 39, 1201-1208.	3.3	8
25	Risk of bias in meta-analysis on erythropoietin-stimulating agents in heart failure. Heart, 2009, 95, 1278-1279.	2.9	7
26	Determining Health-Related Quality of Life and Health State Utility Values of Urinary Incontinence in Women. Female Pelvic Medicine and Reconstructive Surgery, 2011, 17, 305-307.	1.1	7
27	An assessment of annual procedure volumes and therapy adoption of transcatheter closure of patent foramen ovale in four European countries. European Stroke Journal, 2021, 6, 72-80.	5.5	7
28	Cost-effectiveness of orbital atherectomy compared to rotational atherectomy in treating patients with severely calcified coronary artery lesions in Japan. Cardiovascular Intervention and Therapeutics, 2018, 33, 328-336.	2.3	6
29	Cardiovascular Benefits of the Mediterranean Diet Are Driven by Stroke Reduction and Possibly by Decreased Atrial Fibrillation Incidence. American Journal of Medicine, 2016, 129, e11.	1.5	5
30	Deterministic Sensitivity Analysis for First-Order Monte Carlo Simulations: A Technical Note. Value in Health, 2009, 12, 96-97.	0.3	4
31	Treating anemia in heart failure patients: a review of erythropoiesis-stimulating agents. Expert Opinion on Biological Therapy, 2010, 10, 1209-1216.	3.1	4
32	Leadership in health care. Journal of Health Organization and Management, 2010, 24, 258-276.	1.3	4
33	Dyspnea and Chest Pain in a Young Woman Caused by a Giant Pericardial Lymphohemangioma: Diagnosis and Treatment. Canadian Journal of Cardiology, 2016, 32, 1260.e23-1260.e25.	1.7	4
34	Should Surgical Repair Be Recommended Over Nonoperative Management for Medial Meniscus Root Tears? Response. American Journal of Sports Medicine, 2018, 46, NP44-NP45.	4.2	4
35	Study Comparing Traditional Versus Alternative Metrics to Measure the Impact of the Critical Care Medicine Literature. , 2019, 1, e0028.		4
36	Gabapentin Treatment for Alcohol Dependence. JAMA Internal Medicine, 2014, 174, 1201.	5.1	3

#	Article	IF	CITATIONS
37	Adoption Patterns of Bronchoscopic Lung Volume Reduction Procedures in Germany and Predicted Procedure Volumes for Other European Countries. Respiration, 2019, 97, 34-41.	2.6	3
38	Letter to the editor regarding Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. Critical Care, 2021, 25, 285.	5.8	3
39	Cost-Effectiveness of Urea Excipient-Based Drug-Coated Balloons for Chronic Limb-Threatening Ischemia from Femoropopliteal Disease in the Netherlands and Germany. CardioVascular and Interventional Radiology, 2022, 45, 298-305.	2.0	3
40	Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review. Systematic Reviews, 2021, 10, 143.	5.3	2
41	Utilization and Cost Effectiveness of a Risk Stratified Diagnostic Approach to Patients with Suspected Thrombotic Thrombocytopenic Purpura. Blood, 2016, 128, 1456-1456.	1.4	2
42	The Effect of Standardized Hospitalist Information Cards on the Patient Experience: a Quasi-Experimental Prospective Cohort Study. Journal of General Internal Medicine, 0, , .	2.6	2
43	Health State Survey-Derived Utilities in Cost-Utility Analysis—A Call to Action. Value in Health, 2010, 13, 159.	0.3	1
44	PMD23 Long-Term Clinical Effectiveness and Cost-Effectiveness of Catheter-Based Renal Denervation in the UK. A Model-Based Projection Based on the Symplicity HTN-2 Trial. Value in Health, 2012, 15, A349.	0.3	1
45	Health-Economic Assessment of the Use of Catheter-Based Renal Denervation in Patients with Resistant Hypertension in Mexico. Value in Health, 2013, 16, A705.	0.3	1
46	Cost-effectiveness of catheter-based renal denervation for resistant hypertension – a canadian perspective. Value in Health, 2013, 16, A284-A285.	0.3	1
47	Cost-Effectiveness of Transcatheter Aortic Valve Replacement: Current Decision-Analytic Models and Future Opportunities. Value in Health, 2015, 18, A359.	0.3	1
48	Endovascular Interventions For Treatment Of Femoropopliteal Peripheral Artery Disease: Updated Budget Impact Analysis For Germany Based On Latest Clincal Evidence. Value in Health, 2015, 18, A349.	0.3	1
49	Trends in Utilization of Endovascular Arterial Revascularization Modalities Below the Knee in Germany 2009-16. Value in Health, 2018, 21, S177.	0.3	1
50	Hydroxychloroquine Toxicity. Journal of Clinical Rheumatology, 2020, Publish Ahead of Print, .	0.9	1
51	Case management in a <scp>COVID</scp> â€19 surge: A <scp>singleâ€institution</scp> study of disposition and access to <scp>postâ€acute</scp> care. Journal of the American Geriatrics Society, 2022, 70, 372-375.	2.6	1
52	A Diagnostic Model for Kawasaki Disease Based on Immune Cell Characterization From Blood Samples. Frontiers in Pediatrics, 2021, 9, 769937.	1.9	1
53	PHP9 THE IMPACT OF LEGISLATION AND PRICING ON GENERIC DRUG UTILIZATION: AN ANALYSIS OF 26 COUNTRIES. Value in Health, 2009, 12, A80.	0.3	0
54	Perspectives on "Early Dialogue―between a Manufacturer and Health Technology Assessment Agencies. Value in Health, 2011, 14, 607.	0.3	0

#	Article	IF	CITATIONS
55	PMD57 New Approaches for Graphing Probabilistic Patient-Relevant Health Outcomes: The Case of Renal Denervation for Resistant Hypertension. Value in Health, 2012, 15, A72.	0.3	0
56	PMD20 Budget Impact of Drug Eluting Balloons for Intermittent Claudication From Superficial Femoral Artery Disease in the United States Health Care System. Value in Health, 2012, 15, A348.	0.3	0
57	Gender differences in added benefit of catheter-based renal denervation for resistant hypertension: model-based estimation of unadjusted and quality-adjusted life year gains in males and females. European Heart Journal, 2013, 34, P4491-P4491.	2.2	0
58	Estimated Added Benefit Of Catheter-Based Renal Denervation For Moderate Treatment-Resistant Hypertension: Impact Of Age And Cardiovascular Risk Factors. Value in Health, 2014, 17, A474.	0.3	0
59	Adoption Of Transcatheter Aortic Valve Replacement In Germany: Utilization Patterns And Case Volumes Compared To Surgical Aortic Valve Replacement In The Period 2009-2013. Value in Health, 2015, 18, A370.	0.3	0
60	Economic Analysis of Endovascular Interventions for The Treatment of Femoropopliteal Peripheral Artery Disease in Austria. Value in Health, 2016, 19, A690.	0.3	0
61	Economic Analysis of Drug-Coated Balloons And Other Endovascular Treatments For Femoropopliteal Artery Disease In The United Kingdom. Value in Health, 2016, 19, A5.	0.3	0
62	COST EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION VERSUS SURGICAL AORTIC VALVE REPLACEMENT: THE COREVALVE HIGH RISK TRIAL FROM A DUTCH PERSPECTIVE. Value in Health, 2016, 19, A305.	0.3	0
63	Response to Lee etÂal Journal of Thoracic Oncology, 2017, 12, e152-e153.	1.1	0
64	Clinical And Economic Benefit Of Upper Airway Stimulation For Obstructive Sleep Apnea In The German Setting. Value in Health, 2017, 20, A581.	0.3	0
65	PMD54 - DRUG-COATED BALLOON THERAPY FOR TREATMENT OF CRITICAL LIMB ISCHEMIA IN FEMOROPOPLITEAL ARTERY DISEASE: ECONOMIC ANALYSIS FOR THE NETHERLANDS. Value in Health, 2018, 21, S252.	0.3	0
66	Economic Analysis of Urea-Excipient Drug-Coated Balloon Therapy for Treatment of Femoropopliteal Artery Disease in Japan. Value in Health, 2018, 21, S7.	0.3	0
67	Budget Impact of Orbital Atherectomy Compared to Rotational Atherectomy in Patients with Severely Calcified Coronary Artery Lesions in Japan. Value in Health, 2018, 21, S69.	0.3	0
68	PIN44 A MODEL TO EVALUATE THE IMPACT OF HOSPITAL-BASED INTERVENTIONS TARGETING FALSE-POSITIVE BLOOD CULTURES ON ECONOMIC AND CLINICAL OUTCOMES. Value in Health, 2019, 22, S201.	0.3	0
69	Additional Factors That Could Improve Cost-Effectiveness of Pharmacogenetic-Guided Dosing in Warfarin Therapy. Annals of Internal Medicine, 2009, 151, 71.	3.9	0
70	Do Insurers Compete on the Federal Health Insurance Exchange?. F1000Research, 0, 4, 25.	1.6	0
71	Prior Statin Use Is Associated with Decreased Mortality and Lower Levels of Liver and Brain Organ Failure Scores in Sepsis - A Matched Observational Study. SSRN Electronic Journal, 0, , .	0.4	0
72	Cost-effectiveness of programmed cell death protein 1/programmed death-ligand 1 inhibitors (aPD1/aPDL1) varies widely Journal of Clinical Oncology, 2019, 37, e18351-e18351.	1.6	0